Recognition of non-operating income and extraordinary gain
Modalis Therapeutics Corporation (the Company)
Foreign-currency-denominated assets and liabilities held by the Group, and a business partner to which research and development expenses were paid in prior fiscal years
Fluctuations in foreign exchange rates, mainly affecting the foreign-currency-denominated assets and liabilities held by the Group, and the refund of research and development expenses paid to a business partner in prior fiscal years
¥6 million foreign exchange gain (non-operating income) and ¥36 million received as a refund (gain on collection of written-off receivables, extraordinary gain)
Cumulative second-quarter period of the fiscal year ending December 2026 (1 January 2026 to 30 June 2026)
The amount of the foreign exchange gain will fluctuate depending on future foreign exchange rate conditions.
| Item | Details |
|---|---|
| Event name | Recognition of non-operating income and extraordinary gain |
| Subject Entity | Modalis Therapeutics Corporation (the Company) |
| Target Locations / Products | Foreign-currency-denominated assets and liabilities held by the Group, and a business partner to which research and development expenses were paid in prior fiscal years |
| Cause | Fluctuations in foreign exchange rates, mainly affecting the foreign-currency-denominated assets and liabilities held by the Group, and the refund of research and development expenses paid to a business partner in prior fiscal years |
| Amount of Impact on Business Performance | ¥6 million foreign exchange gain (non-operating income) and ¥36 million received as a refund (gain on collection of written-off receivables, extraordinary gain) |
| Accounting period in which recognized | Cumulative second-quarter period of the fiscal year ending December 2026 (1 January 2026 to 30 June 2026) |
| Outlook | The amount of the foreign exchange gain will fluctuate depending on future foreign exchange rate conditions. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Foreign exchange gains arose mainly from fluctuations in foreign exchange rates affecting the foreign-currency-denominated assets and liabilities held by the Group. In addition, the Company received a refund from a business partner for research and development expenses paid to that business partner in prior fiscal years.